OncoDaily

The Precision Oncology Potential Here For ccRCC is Real - Katy Beckermann @katy_beckermann oncodaily.com/voices/katy-be… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

Shocking Disparities in Utilization of Essential Cancer Meds - Harold J. Burstein @DrHBurstein oncodaily.com/voices/harold-… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

PI3Ki Zovegalisib and Fulvestrant Presented at ESMOTAT 2026 - Paolo Tarantino @PTarantinoMD oncodaily.com/voices/paolo-t… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

🌐 𝗖𝘂𝗿𝘃𝗲𝗱 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗼𝗿𝘀 𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗶𝗻𝗴 𝗦𝗸𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 🌐 • The “Nautilus Effect” shows how curvature optimizes dose delivery. • Concave and convex regions behave differently, here’s how! • Future treatment plans could be shaped by personalized applicator designs. 📖 𝗖𝘂𝗿𝗶𝗼𝘂𝘀 𝘁𝗼 𝗹𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲? 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗻𝗼𝘄ⵑ oncodaily.com/oncolibrary/ra… #OncoDaily #SkinCancer #Brachytherapy #MedicalResearch #NautilusEffect

World Child Cancer - A Decade of Collaboration Strengthening Paediatric Oncology Services Across Cameroon @WChildCancer @Collective_FS oncodaily.com/voices/paediat… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX

@cspramesh @uicc @WHO @iaeaorg @IARCWHO @CancerGridIndia @theNCI @NCICancerCtrl @ASCO @myESMO @WHO_Europe @CCan_org @csoncol We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/pramesh…

The scientific content with the World Cancer Congress is amazing. Do register, and join this people-centric event. @uicc @WHO @iaeaorg @IARCWHO @CancerGridIndia @theNCI @NCICancerCtrl @ASCO @myESMO @WHO_Europe @CCan_org @csoncol @oncodaily

@dr_dirican We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/ahmet-d…

Do ctDNA-based multicancer early detection (MCED) tests lead to overdiagnosis? A new 5-year analysis from the case-control Circulating Cell-free Genome Atlas (CCGA) study explored the prognostic meaning of MCED results. (CSD = cancer signal detected | NCSD = no cancer signal detected) Key findings: • CSD: 5-yr OS 43% vs 40% in matched SEER population • NCSD: 5-yr OS 88% vs 81% in SEER Importantly, early-stage CSD cancers had survival similar to the matched SEER population, suggesting MCED is unlikely to simply detect indolent tumors (i.e., limited evidence of overdiagnosis). But a critical clinical question remains: If early-stage cancers are CSD-positive (ctDNA detected), should they be managed differently? @oncodaily #OncoAlert @JCO_ASCO @JCOOP_ASCO @ASCOPost @OncBrothers @mtmdphd ascopubs.org/doi/10.1200/PO…

Long-Term Cardiac Risks in Hodgkin Lymphoma Survivors - Khushali J. @JhaveriKhushali oncodaily.com/voices/khushal… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

@MamthaB We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/mamtha-…

🧬 DLBCL – Rapid Board Review Pearls (Follow NCCN/ASH/ASCO for latest updates) 🧠 Mnemonic: “My MUM taught me the ABCs” →  MUM1+ = ABC (activated B‑cell, worse prognosis) CD10+ → GCB (germinal center B‑cell, better) CD10– + BCL6+/MUM1– → GCB CD10– + MUM1+ → ABC 🧠Frontline Regimens: “Pola 💃Replaces Vince🕺” Standard: R‑CHOP High‑risk: Pola‑R‑CHP (Polatuzumab replaces Vincristine) 🧠“8 hits HARD” MYC (chr 8) + BCL2/BCL6 → aggressive Treat with DA-R-EPOCH + CNS prophylaxis 🧠Big nodes, 10 is good, MUM is bad, 8 hits hard, 100 = Burkitt, early relapse → CAR 1️⃣ Presentation & Workup 🩺 Painless LAD + B-symptoms (fever, drenching sweats, weight loss). 👋 Examine neck, axilla, groin nodes. 🧪 Labs: CBC, CMP, LDH, Hep B, HIV. 📸 Imaging: PET/CT for staging (CT neck/chest/abd/pelvis if inpatient). 2️⃣ Diagnosis & Pathology 🔬 🧱 Biopsy gold standard: Excisional (or core) to see architecture. ⚠️ FNA = triage only, NOT definitive for lymphoma. 🧫 IHC B‑cell markers: CD19, CD20, CD22, CD79a, PAX5. 📈 Ki‑67 often high (~80%); Ki‑67 ~100% → think Burkitt until proven otherwise (MYC+). 3️⃣ Cell of Origin (Hans Algorithm) 🧬 GEP: GCB > ABC for prognosis. Hans IHC rules:CD10+ → GCB ✅ CD10– & BCL6+/MUM1– → GCB CD10– & (BCL6– or MUM1+) → ABC / non‑GCB 🔑 Prognostic, not predictive – doesn’t routinely change frontline choice. 4️⃣ Genetics – “Hits” & Expressors 🧨 Chromosomes: MYC → chr 8 (“8‑ball”; drives S‑phase). BCL2 → chr 18, anti‑apoptotic, t(14;18). BCL6 → chr 3, represses MYC/BCL2/p53. Double/Triple HIT (FISH – structural) Double hit (DH) = MYC + BCL2 and/or BCL6 rearrangements. Triple hit (TH) = MYC + BCL2 + BCL6 rearrangements. 🩸 Very poor prognosis → DA‑R‑EPOCH + CNS prophylaxis (not R‑CHOP). 🩸Double EXPRESSOR (DE – IHC) IHC MYC >40% & BCL2 >50%. Worse than standard DLBCL, but less bad than DH/TH. 🧠Many give CNS PPx, but escalation to DA‑EPOCH is controversial. Ki‑67 Pearl📌 🔥 Ki‑67 ≈100% = presume Burkitt → confirm MYC rearrangement, treat with Burkitt-type regimen + CNS PPx. 5️⃣ Staging & Pre‑Treatment 📍 🗺️ Lugano staging (PET‑based)I/II = early (single/bundled nodes on one side of diaphragm). III/IV = advanced (nodes both sides ± extranodal, e.g., marrow/liver). 🧪 LDH = key prognostic marker (IPI). 💉 Hep B serology mandatory before rituximab (reactivation risk). ❤️ Baseline echo before doxorubicin. 🦴 Routine BM biopsy often omitted (PET captures stage; III–IV treated the same). 6️⃣ Frontline Therapy 🚀 🟢 Standard risk:R‑CHOP × 6 cycles (± RT for bulky/early localized). 🟠 Intermediate/High risk (IPI ≥2):Pola‑R‑CHP (Polatuzumab‑vedotin + R‑CHP; VINCRISTINE replaced by pola). 📊 POLARIX: improved PFS vs R‑CHOP. 🔴 Double/Triple hit or PMBL:DA‑R‑EPOCH preferred (etoposide‑based, dose‑adjusted). 📌EOT PET strategy: PET‑positive → consider ctDNA MRD (e.g., CLARITY):ctDNA‑negative + low PET uptake → treat like PET‑negative; avoid unnecessary biopsy/escalation. 7️⃣ Relapsed/Refractory DLBCL 🔁 ⏱️ Early relapse (<12 mo) after R‑CHOP / Pola‑R‑CHP: CAR‑T preferred over salvage + ASCT:Axi‑cel or Liso‑cel. 🕒 Late relapse (≥12 mo):Salvage chemo (R‑ICE, R‑DHAP, R‑GDP) → ASCT if chemosensitive. 🩸3rd line and beyond (Immunotherapy Era) 🧬 Bispecifics (BiTEs):Epcoritamab (SC), Glofitamab (IV), Odronextamab (IV). 🎯 ADCs:Loncastuximab (anti‑CD19), Pola‑BR (polatuzumab + bendamustine + rituximab). 8️⃣ Toxicity Mnemonic – “C‑N‑R” 🛡️ C – CRS (Cytokine Release Syndrome)Seen with CAR‑T & bispecifics: fever, hypotension. Rx: Tocilizumab ± steroids. N – Neurotoxicity (ICANS)CAR‑T: confusion, aphasia, seizures. Close neuro checks, treat with steroids. R – Reactivation (Rituximab)Hep B reactivation → always check serology & start prophylaxis if positive. 9️⃣ Super High‑Yield One‑Liners 💥 ✅ DLBCL = core/excisional LN biopsy; FNA alone is inadequate. ✅ Hans: CD10+ or CD10–/BCL6+/MUM1– = GCB; MUM1+ = ABC. ✅ Double/triple hit (MYC + BCL2/BCL6 by FISH) → DA‑R‑EPOCH + CNS PPx. ✅ Double expressor = MYC/BCL2 protein ↑ by IHC; worse, but less than DH. ✅ Ki‑67 ≈100% = presumptive Burkitt; treat with Burkitt regimen + CNS PPx (not R‑CHOP). ✅ First‑line: R‑CHOP vs Pola‑R‑CHP in higher‑risk de novo DLBCL. ✅ Early relapse (<12 mo): CAR‑T > salvage + ASCT. ✅ 3rd‑line+: bispecifics (epcoritamab, glofitamab, odronextamab), ADCs (loncastuximab, Pola‑BR). ✅ ctDNA MRD now refines PET‑positive EOT scans. Thread caption idea: 🔟Diagnostic Innovation: ctDNA / MRD Monitoring 🧬 ⚡️The Update: NCCN Guidelines (v1.2025/2026) now include circulating tumor DNA (ctDNA) as a tool to clarify end-of-treatment PET scans. ( Journal of Clinical Oncology 2025/2026 update) 🔬 #Lymphoma #DLBCL #mmsm #HemeOnc #MedEd #BloodCancer #CancerResearch #Oncology #HemOnc #Lymphoma #BoardReview @LLSusa @WomenInLymphoma @llmcongress @ASH_hematology @ASCOPost @HemOncToday @OncoAlert @oncodaily @realbowtiedoc @IMG_Oncologists @lymphoma @LymphomaAction

Insurance-Related Barriers Continue to Deny or Delay NGS Testing in NSCLC - Aakash Desai @ADesaiMD oncodaily.com/voices/aakash-… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

Robert H. Vonderheide has been elected AACR President-Elect for 2026–2027 An internationally recognized leader in cancer immunotherapy and Director of the Abramson Cancer Center, his work has significantly advanced translational oncology and modern immuno-oncology He will begin his term in April 2026 at the AACR Annual Meeting in San Diego and is expected to assume the presidency in 2027 @lillian_siu @AACR @AACR_CEO oncodaily.com/community/robe… #AACR #Oncology #CancerResearch #Immunotherapy #Leadership #OncoDaily #MedX

Making Cancer Care Accessible Through Distributed Cancer Care Models: Dr. Moni Abraham Kuriakose In this episode of Global Health Unpacked, host Dr. Gvantsa Khizanishvili sits down with Dr. Moni Abraham Kuriakose, Co-Founder, Medical Director and CEO of Karkinos Healthcare (@karkinoshealth), Professor and Vice Chairman at Roswell Park Comprehensive Cancer Center, to explore how distributed cancer care models can transform the future of global oncology. Together, they discuss the urgent need to rethink traditional cancer care systems, and how innovation, technology, and collaboration can help address the rapidly growing global cancer burden. Key Topics: ✅ Why cancer is no longer a rare disease, and the implications for global health systems ✅ The shift from centralized cancer centers to distributed, patient-centered care models ✅ How empowering primary care providers can lead to earlier diagnosis and better outcomes ✅ The role of technology, AI, and virtual tumor boards in enabling decentralized care youtu.be/1SPNbr-yjZs?si… #GlobalHealth #OncoDaily #Oncology #Cancer #Health #Medicine

All.Can International and SPCC to Host Webinar on Efficiency in Precision Oncology @AllCanGroup. . oncodaily.com/voices/all-can… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #PrecisionOncology

Tumor Debulking in Metastatic Colorectal Cancer - Jason Denbo and Syed A. Ahmad @DenboJw @SyedAAhmad5 oncodaily.com/voices/jason-w… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

@dr_dirican We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/ahmet-d…

Trastuzumab deruxtecan + SRS in brain metastases T-DXd combined with SRS: ➡️ Did not increase radionecrosis risk ➡️ Improved intracranial disease control However… Key limitations of this study: Retrospective design Small sample size (especially T-DXd cohort) Shorter follow-up in T-DXd group (late RN may be missed) Dosimetric imbalances (smaller lesions, lower RT doses) Heterogeneous control group (including T-DM1) Potential immortal time bias Bottom line: 👉 Promising results 👉 But not sufficient to conclude this combination is fully safe in routine practice yet. thebreastonline.com/article/S0960-… @oncodaily @OncBrothers @myESMO @ASCOPost @PTarantinoMD

@raffcolo @BarbaraPistill2 @MDAndersonnews @CD_AACR @myESMO We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/raffael…

#ESMOTAT26 is wrapping up! It was a great pleasure to discuss ADCs from an industry perspective with @BarbaraPistill2 and Funda Meric-Bernstam (@MDAndersonNews)! Bonus: updated ADC landscape with same format of our @CD_AACR 2024 review and some fun with ADC PK ☺️ @myESMO

Between Patients and Machines: The Human Side of Radiation Oncology Radiation oncology is a specialty defined as much by its challenges as by its technology. Across continents, radiation oncologists describe working at the intersection of life-saving innovation and persistent systemic obstacles — limited resources, workforce shortages, administrative burden, unequal access to care, and the emotional weight of treating patients with serious illness. While the machines grow more sophisticated, many clinicians feel the human and structural support around them has not kept pace. oncodaily.com/oncolibrary/ra… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

Youth Cancer Europe - The EU Cancer Mission Dialogue @CancerEurope oncodaily.com/voices/youth-c… #OncoDaily #Oncology #Cancer #Health #Medicine

SPCC Symposium at @CancerCareMASCC 2026 Addresses Gaps in MEC Management oncodaily.com/voices/spcc-47… #OncoDaily #Oncology #Cancer #Health #Medicine #MASCC2026 #MedX

CancerWorld - The Day Immunotherapy Went Off-Patent @CancerWorldmag @amalsargsyan oncodaily.com/voices/immunot… #OncoDaily #Oncology #Cancer #Health #Medicine #Immunotherapy #MedX